盘后交易 18:30 (美东)46.010USD+0.160+0.35%关键数据
44.190今开
44.650最高
281.23K成交量
49.40市盈率 TTM
72.83市盈率动
--股息TTM
0.17%换手率
44.540昨收
44.070最低
12.77M成交额
20.99市盈率静
4.13市净率
0.00%股息率 TTM
4.82%ROA
55.67052周最高
59.54量比
367.07M净利润
167.76M总股本
0.9298每股收益TTM
0.31Beta
9.36%ROE
27.00052周最低
5.56%振幅
77.51%毛利率
7.70B总市值
-2.28回报/风险
2.55%风险率

即将为您带来更多新闻,敬请期待。。。
Alkermes Plc评分
0.03与上次评分对比预测7.70
财务诊断8.22
技术分析4.29
公司估值8.77
机构认同度10.00
风险评估7.49
分析师评级
买入评级
56.259目标均价
+24.08%涨幅空间
Alkermes Plc 最新财报电话会记录
Alkermes (ALKS) 2026年第三季度业绩电话会议:营收4.801亿美元与食欲素催化剂
由于专有产品销售额增长31%,Alkermes 2026年第三季度营收达到4.801亿美元。管理层维持了业绩指引,并概述了即将公布的六项食欲素(orexin)临床数据。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Alkermes Plc 简介
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
行业生物技术与医疗研究
公司代码ALKS
员工数量1800
国家Ireland
持股情况
| 持股股东 | 占比 |
|---|
| BlackRock Institutional Trust Company, N.A. | 14.44% |
|---|
| Baker Bros. Advisors LP | 6.01% |
|---|
| Vanguard Portfolio Management, LLC | 5.71% |
|---|
| State Street Investment Management (US) | 5.68% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor | 53.46% |
|---|
| Investment Advisor/Hedge Fund | 29.75% |
|---|
| Hedge Fund | 19.22% |
|---|
| Research Firm | 2.48% |
|---|
常见问题
Alkermes Plc(ALKS)的当前股价是多少?
Alkermes Plc(ALKS)的当前股价是 45.90。
Alkermes Plc股票的52周最高点是多少?
Alkermes Plc股票的52周最高点是55.67。
Alkermes Plc股票的52周最低点是多少?
Alkermes Plc股票的52周最低点是27.00。
现在Alkermes Plc(ALKS)的股票是买入、持有还是卖出?
根据分析师评级,Alkermes Plc(ALKS)的总体评级为买入,目标价格为56.26。
Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是多少
Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是0.93。